Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Share-based Compensation (2016 - 2026)

Pharma-Bio Serv's Share-based Compensation history spans 17 years, with the latest figure at $8619.0 for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 19.31% year-over-year to $8619.0; the TTM value through Jan 2026 reached $33017.0, down 23.97%, while the annual FY2025 figure was $35079.0, 26.22% down from the prior year.
  • Share-based Compensation reached $8619.0 in Q1 2026 per PBSV's latest filing, up from $4399.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $28445.0 in Q4 2022 to a low of $684.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $12233.7, with a median of $14400.0 recorded in 2022.
  • Peak YoY movement for Share-based Compensation: tumbled 97.6% in 2023, then skyrocketed 359.94% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $28445.0 in 2022, then crashed by 97.6% to $684.0 in 2023, then surged by 359.94% to $3146.0 in 2024, then skyrocketed by 39.83% to $4399.0 in 2025, then skyrocketed by 95.93% to $8619.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Share-based Compensation are $8619.0 (Q1 2026), $4399.0 (Q4 2025), and $9999.0 (Q3 2025).